FDA Drug Safety Newsletter
admin January 19th, 2009
The FDA Drug Safety Newsletter Volume 2, Number 1, 2009, has been published. It includes three postmarket reviews:
Varenicline and Bubropion: Reports of suicidality associated with use of varenicline (marketed as CHANTIX) and bupropion (marketed as ZYBAN and GENERICS)
Abacavir: Information for healthcare professionals on an abacavir (marketed as ZIAGEN, EPZICOM, and TRIZIVIR) hypersensitivity reaction, HLA-B*5701, and skin patch testing
Atomoxetine: Reports of serious liver injury associated with use of atomoxetine (marketed as STRATTERA)
- FDA
- Comments Off